000279491 001__ 279491
000279491 005__ 20250709100939.0
000279491 037__ $$aDZNE-2025-00818
000279491 1001_ $$0P:(DE-2719)2810938$$aMüller, Stephan A$$b0$$udzne
000279491 245__ $$aDataset: Plasma proteomics of BACE2 KO mice
000279491 260__ $$bPRoteomics IDEntifications Database$$c2024
000279491 3367_ $$2BibTeX$$aMISC
000279491 3367_ $$0PUB:(DE-HGF)32$$2PUB:(DE-HGF)$$aDataset$$bdataset$$mdataset$$s1752047302_8072
000279491 3367_ $$026$$2EndNote$$aChart or Table
000279491 3367_ $$2DataCite$$aDataset
000279491 3367_ $$2ORCID$$aDATA_SET
000279491 3367_ $$2DINI$$aResearchData
000279491 520__ $$aThe beta-secretase BACE1 is a central drug target for Alzheimer’s disease. Clinically tested, BACE1-directed inhibitors also block the homologous protease BACE2. Yet, little is known about physiological BACE2 substrates and functions in vivo. Here, we performed discovery proteomics to identify substrates of the protease BACE2 in plasma of mice. Therefore, we analysed plasma from BACE2 KO, and WT controls. Inactivation of BACE2 inhibited shedding of VEGFR3/FLT4. Thus, sVEGFR3 represents a pharmacodynamic plasma marker for BACE2 activity in vivo.
000279491 536__ $$0G:(DE-HGF)POF4-352$$a352 - Disease Mechanisms (POF4-352)$$cPOF4-352$$fPOF IV$$x0
000279491 7001_ $$0P:(DE-2719)2181459$$aLichtenthaler, Stefan$$b1$$udzne
000279491 7870_ $$0DZNE-2024-01041$$aSchmidt, Andree et.al.$$dAnn Arbor, Mich. : ASCJ, 2024$$iRelatedTo$$r$$tThe Alzheimer's disease-linked protease BACE2 cleaves VEGFR3 and modulates its signaling.
000279491 8564_ $$uhttps://wwwdev.ebi.ac.uk/pride/archive/projects/PXD041579
000279491 909CO $$ooai:pub.dzne.de:279491$$pVDB
000279491 9101_ $$0I:(DE-588)1065079516$$6P:(DE-2719)2810938$$aDeutsches Zentrum für Neurodegenerative Erkrankungen$$b0$$kDZNE
000279491 9101_ $$0I:(DE-588)1065079516$$6P:(DE-2719)2181459$$aDeutsches Zentrum für Neurodegenerative Erkrankungen$$b1$$kDZNE
000279491 9131_ $$0G:(DE-HGF)POF4-352$$1G:(DE-HGF)POF4-350$$2G:(DE-HGF)POF4-300$$3G:(DE-HGF)POF4$$4G:(DE-HGF)POF$$aDE-HGF$$bGesundheit$$lNeurodegenerative Diseases$$vDisease Mechanisms$$x0
000279491 9201_ $$0I:(DE-2719)1110006$$kAG Lichtenthaler$$lNeuroproteomics$$x0
000279491 980__ $$adataset
000279491 980__ $$aVDB
000279491 980__ $$aI:(DE-2719)1110006
000279491 980__ $$aUNRESTRICTED